Navigation Links
Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
Date:7/15/2009

CALGARY, July 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation by Dr. Jacqueline Parker et al. entitled "Anti-Tumor Activity of Reovirus is Synergistically Enhanced in Combination with Temozolomide and Low Dose Irradiation in Primary Patient Glioma Xenografts Resistant to Treatment with Either Therapy Alone" was made yesterday at the 28th American Society for Virology (ASV) Annual Meeting. The meeting is being held in Vancouver, British Columbia, from July 11-15, 2009.

"These results support the strategic direction we're taking with the REOLYSIN(R) clinical program," said Dr. Matt Coffey, Chief Operating Officer for Oncolytics. "The future program for REOLYSIN, including our pivotal program, is focused on exploiting these underlying drug synergies."

The poster covers preclinical work using reovirus in combination with low dose irradiation (IR) and temozolomide (TMZ). A panel of glioma cell lines and primary patient glioma explant cells were tested for susceptibility to reovirus, IR, TMZ, or a combination of these therapies in vitro. The combination index analyses revealed moderate to strong synergy in primary patient glioma cells treated with reovirus plus IR and TMZ in vitro. This effect was also seen in vivo in flank tumor xenografts from primary patient tumors resistant to reovirus therapy alone.

The investigators concluded that the data supports the use of reovirus in combination with standard radiation and chemotherapies for the treatment of malignant glioma in humans.

The poster will be available on the Oncolytics website at www.oncolyticsbiotech.com at a later date.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the de
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
4. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
5. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
6. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
7. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
8. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
9. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
10. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. , ... viral vectors, nonviral vectors and cell therapy with ... method of drug delivery and various routes of ...
(Date:3/3/2015)... DNA Diagnostics Center (DDC), one of the largest ... 20 th anniversary today. Headed by President and ... services company that focuses on DNA testing across multiple ... generates a significant portion of sales across international markets ... Peter Vitulli acknowledges the anniversary of the ...
(Date:3/3/2015)... March 3, 2015  PDL BioPharma, Inc. (PDL or ... that the third of three shareholder lawsuits filed in ... On February 2, 2015, a securities lawsuit ... behalf of a putative class of purchasers of the ... No. 2:14-CV-01526-APG-NJK (D. Nev.), was voluntarily dismissed without prejudice.  ...
(Date:3/2/2015)... MD and Fort Washington, PA (PRWEB) March 02, 2015 ... Genetics (ASHG) and ReachMD announced today ... of audio interviews designed to educate healthcare professionals on ... management. , The series features peer-to-peer interviews ... topics such as:, ,     Translational Genomics and ...
Breaking Biology Technology:Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 2DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 3PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit 2American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 2American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 3
... 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... has been appointed Senior Vice President, General Counsel and ... of the Company,s legal affairs, including general corporate legal ... to Leonard S. Schleifer, M.D., Ph.D., president and chief ...
... Sept. 6, 2011 ChromaDex Corporation (OTCBB: CDXC) announced ... Jr., will be presenting the company,s business strategy and ... Global Investment Conference. The event will be held September ... City. ChromaDex is scheduled to make its ...
... announces that a new market research report ... Industrial Biotechnology China News 1108 ... In this issue, Grandhope,s getting listed successfully ... the medical device industry. And this issue ...
Cached Biology Technology:Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary 2ChromaDex to Present at the Rodman & Renshaw Annual Global Investment Conference 2Industrial Biotechnology China News 1108 2Industrial Biotechnology China News 1108 3
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... proven effectiveness thanks to their appetite-suppressing effects. A team ... "Nutrition and the Brain" in Lyon, has managed to ... describe in detail the chain reactions triggered by digesting ... after a meal. Their results, published on 5 July ...
... A traffic policeman standing at a busy intersection directing the ... but a similar scene appears to still frequently play out ... step of cell division by preventing the progress of one ... Biology Laboratory (EMBL) in Heidelberg, Germany, have found. The study ...
... coral reefs to a total ecosystem collapse lasting thousands of ... Science . The paper shows how natural climatic shifts stopped ... reef shutdown, which began 4,000 years ago, corresponds to a ... "As humans continue to pump greenhouse gases into the atmosphere, ...
Cached Biology News:The 'appetite-suppressing' effect of proteins explained 2Stop and go 2Climate change suspended reef growth for 2 millennia 2
IHC detection kit for PCNA in cells and tissues...
... Immunogen: Synthetic peptide derived from the ... protein. Specificity: Reacts with the ... Reactivity: Human Mouse (positive controls: WNT1-transfected ... lysates and mouse Mouse-1 cell lysates). ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
... [125I] Direct SPA Screening Assay, ... reagents that eliminate lengthy sample extraction ... (optional use).Range: 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: ... at 2-8 C. Category: Drug Screening ...
Biology Products: